Zhitong Finance App News, Yuanda Pharmaceutical (00512.HK) issued an announcement. Recently, the first patient was enrolled in the Phase III clinical study of GPN01360, the Group's innovative traditional Chinese medicine drug for treating depression in China. This is a major milestone in the Group's proprietary Chinese medicine sector.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.